Researchers
-
Ana Sánchez Escuredo
Nephrology
Phd -
Cristina Cabrera López
Nephrology
-
Isabel Bueno López
Nephrology
-
Isabel Giménez Torrecilla
Nephrology
-
Meritxell Ibernon Vilaró
Nephrology
Phd -
Neus Rodríguez Farré
Nephrology
-
Oana Rap
Nephrology
-
Pilar Ruiz Valverde
Nephrology
Contact the group
Form
Projects
-
Nephrology
Researcher
- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in reducing cardiovascular morbidity and mortality in patients with diabetes Mellitus Type 2 and clinical diagnosis of diabetic nephropathy
-
DISTRICT ATTORNEY:
BAYER AG
-
TYPE E:
RD2015
-
- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Non-interventional study to investigate the safety, effectiveness and adherence of Velphoro® in the short and long term in real life in patients with hyperphosphatemia undergoing hemodialysis (HD) or peritoneal dialysis (PD)
-
DISTRICT ATTORNEY:
Vifor Fresenius Medical Care Renal Pharma
-
TYPE E:
EPA
-
- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Double-blind, randomized, placebo-controlled study to evaluate the effect of SNF472 on the progression of cardiovascular calcification in addition to the reference treatment in patients with end-stage nephropathy (NT) undergoing hemodialysis (HD)
-
DISTRICT ATTORNEY:
Sanifit Laboratories
-
TYPE E:
RD2015
-
- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in reducing cardiovascular morbidity and mortality in patients with diabetes Mellitus Type 2 and clinical diagnosis of diabetic nephropathy
-
DISTRICT ATTORNEY:
BAYER AG
-
TYPE E:
RD2015
-
Nephrology
Researcher
- Year 2016
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in the progression of renal disease in patients with Type 2 Diabetes Mellitus XNUMX and clinical diagnosis of diabetic nephropathy
-
DISTRICT ATTORNEY:
Bayer Healthcare AG
-
TYPE E:
RD2015
-
- Year 2016
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in the progression of renal disease in patients with Type 2 Diabetes Mellitus XNUMX and clinical diagnosis of diabetic nephropathy
-
DISTRICT ATTORNEY:
Bayer Healthcare AG
-
TYPE E:
RD2015
-
- Year 2016
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in the progression of renal disease in patients with Type 2 Diabetes Mellitus 2 and clinical diagnosis of diabetic nephropathy
-
DISTRICT ATTORNEY:
Bayer Healthcare AG
-
TYPE E:
RD2015
Lines of action
- Line of Research in Clinical Nephrology: A Study of Renal Progression Factors in Diabetic Nephropathy
- Dialysis Research Line
- Renal
